SCHEMBL23973121

SCHEMBL23973121

CC(C)(C)OC(=O)N1CCc2nc(C3(c4cc(C5CCCCC5)cs4)CC3)[nH]c(=O)c2C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPR P35270 6/20 0.36
DDB1 Q16531 3/20 0.36
CRBN Q96SW2 3/20 0.36
PDE4B Q07343 1/20 0.35
PDE7A Q13946 1/20 0.35
MAPT P10636 2/20 0.34
FABP4 P15090 1/20 0.34
FABP5 Q01469 1/20 0.34
F12 P00748 1/20 0.34
PARP1 P09874 1/20 0.33
TNKS2 Q9H2K2 1/20 0.33
PARP2 Q9UGN5 1/20 0.33
KDM4E B2RXH2 2/20 0.33
GCK P35557 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CRHBP P24387 1/20 0.33
KMT2A Q03164 1/20 0.33
CRHR2 Q13324 1/20 0.33
THRB P10828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23973111 1.00 SPR (0.36) SPRDDB1CRBNPDE4BPDE7A
SCHEMBL23973109 0.99 SPR (0.36) SPRDDB1CRBNPDE4BPDE7A
SCHEMBL23973324 0.96 SPR (0.37) SPRDDB1CRBNPDE4BPDE7A
SCHEMBL26602845 0.95 SPR (0.37) SPRDDB1CRBNPDE4BPDE7A
SCHEMBL26602936 0.92 MTOR (0.36) SPRDDB1CRBNPDE4BPDE7A
SCHEMBL23973325 0.89 SPR (0.36) SPRDDB1CRBNPDE4BPDE7A
SCHEMBL23973271 0.86 MAPT (0.37) SPRDDB1CRBNMAPTFABP4
SCHEMBL23973297 0.86 SPR (0.39) SPRDDB1CRBNMAPTFABP4
SCHEMBL23972865 0.85 F12 (0.39) SPRDDB1CRBNMAPTF12
SCHEMBL23972866 0.85 SPR (0.36) SPRDDB1CRBNMAPTFABP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4142874-B1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC (JP) 2026-04-22 EP disclosed
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US disclosed
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US disclosed
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US disclosed
WO-2021221169-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS TRPV4, TRPV1, TRPV2 SPR 840/4885DDB1 2439/4885CRBN 4777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.